Table 1.
Patient characteristics
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| <75 years | ≥75 years | P value | <75 years | ≥75 years | P value | |
| Number of patients | 2536 | 703 | 397 | 397 | ||
| Gender, n (%) | ||||||
| Male | 1939 (76.5) | 502 (71.4) | 0.0060 | 310 (78.1) | 292 (73.6) | 0.1357 |
| Female | 597 (23.5) | 201 (28.6) | 87 (21.9) | 105 (26.5) | ||
| Age, years | 62.0 ± 9.1 | 78.4 ± 3.1 | <0.0001 | 63.0 ± 8.5 | 78.1 ± 2.6 | <0.0001 |
| Weight, kg | 60.1 ± 11.7 | 55.3 ± 9.8 | <0.0001 | 59.6 ± 11.6 | 55.3 ± 9.8 | <0.0001 |
| BMI, kg/m2 | 22.5 ± 3.6 | 22.0 ± 3.1 | 0.0070 | 22.4 ± 3.5 | 22.0 ± 3.2 | 0.1712 |
| ECOG PS, n (%) | ||||||
| 0 | 1682 (66.3) | 401 (57.0) | <0.0001 | 227 (57.2) | 225 (56.7) | 0.8758 |
| 1 | 733 (28.9) | 261 (37.1) | 142 (35.8) | 147 (37.0) | ||
| ≥2 | 121 (4.8) | 41 (5.8) | 28 (7.1) | 25 (6.3) | ||
| eGFR (mL/min/1.73 m2) | 55.9 ± 22.0 | 47.9 ± 17.6 | <0.0001 | 53.7 ± 19.5 | 47.5 ± 15.5 | <0.0001 |
| TNM stage, n (%) | ||||||
| I | 8 (0.3) | 9 (1.3) | <0.0001 | 0 (0.0) | 1 (0.3) | 0.5297 |
| II | 5 (0.2) | 4 (0.6) | 0 (0.0) | 1 (0.3) | ||
| III | 27 (1.1) | 18 (2.6) | 2 (0.5) | 3 (0.8) | ||
| IV | 2492 (98.3) | 672 (95.6) | 395 (99.5) | 392 (98.7) | ||
| Unknown | 4 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Prior surgery, n (%) yes/no | 2139 (84.4) / 397 (15.7) | 564 (80.2) / 139 (19.8) | 0.0093 | 365 (91.9) / 32 (8.1) | 367 (92.4) / 30 (7.6) | 0.7914 |
| Prior systemic anticancer therapy, n (%) | ||||||
| Any | 2034 (80.2) | 538 (76.5) | 0.0330 | 330 (83.1) | 330 (83.1) | 1.0000 |
| No | 502 (19.8) | 165 (23.5) | 67 (16.9) | 67 (16.9) | ||
| Primary diseasea, n (%) | ||||||
| Unresectable/metastatic RCC | 2502 (98.7) | 698 (99.3) | 0.1757 | 397 (100.0) | 397 (100.0) | 1.0000 |
| Other than unresectable/metastatic RCC | 40 (1.6) | 7 (1.0) | 0.2539 | 0 (0.0) | 0 (0.0) | 1.0000 |
| Subtype, n (%) | ||||||
| Clear cell carcinoma | 1867 (73.6) | 497 (70.7) | 0.3599 | 335 (84.4) | 346 (87.2) | 0.2638 |
| Non-clear cell carcinoma | 259 (10.2) | 60 (8.5) | 62 (15.6) | 51 (12.9) | ||
| Metastatic site, n (%) | ||||||
| Any | 2472 (97.5) | 670 (95.3) | 0.0028 | 392 (98.7) | 387 (97.5) | 0.1925 |
| Bone | 823 (32.5) | 184 (26.2) | 0.0015 | 106 (26.7) | 115 (29.0) | 0.4761 |
| Brain | 144 (5.7) | 25 (3.6) | 0.0252 | 19 (4.8) | 17 (4.3) | 0.7330 |
| Liver | 405 (16.0) | 87 (12.4) | 0.0188 | 48 (12.1) | 48 (12.1) | 1.0000 |
| Lung | 1809 (71.3) | 491 (69.8) | 0.4413 | 293 (73.8) | 288 (72.5) | 0.6888 |
| Lung only | 628 (24.8) | 211 (30.0) | 131 (33.0) | 124 (31.2) | ||
| Kidney | 187 (7.4) | 50 (7.1) | 0.8138 | 27 (6.8) | 32 (8.1) | 0.4987 |
| Other (including lymph nodes) | 1115 (44.0) | 287 (40.8) | 0.1368 | 164 (41.3) | 152 (38.3) | 0.3843 |
| AST (IU/L) | 26.5 ± 31.1 | 24.9 ± 17.6 | 0.2353 | 25.5 ± 21.0 | 25.0 ± 18.5 | 0.7668 |
| ALT (IU/L) | 24.2 ± 28.5 | 20.0 ± 20.6 | 0.0006 | 23.8 ± 27.4 | 20.3 ± 23.0 | 0.0563 |
| T-Bil (mg/dL) | 0.55 ± 0.34 | 0.57 ± 0.61 | 0.4028 | 0.55 ± 0.32 | 0.57 ± 0.62 | 0.6742 |
| LDH (mg/dL) | 229.3 ± 260.1 | 225.9 ± 208.1 | 0.7711 | 207.5 ± 118.4 | 220.0 ± 228.5 | 0.3432 |
| CRP, mg/dL | 3.15 ± 5.20 | 2.53 ± 4.01 | 0.0122 | 2.19 ± 3.98 | 2.30 ± 3.98 | 0.7145 |
| MSKCC risk (1999)b, n (%) | ||||||
| Favourable | 451 (17.8) | 87 (12.4) | 0.0066 | 81 (20.4) | 70 (17.6) | 0.1443 |
| Intermediate | 1413 (55.7) | 414 (58.9) | 265 (66.8) | 259 (65.2) | ||
| Poor | 143 (5.6) | 35 (5.0) | 18 (4.5) | 14 (3.5) | ||
Data are expressed as mean ± SD unless otherwise indicated.
BMI body mass index, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, eGFR estimated glomerular filtration rate, MSKCC Memorial Sloan Kettering Cancer Center, RCC renal cell carcinoma, TNM tumour, node, metastasis.
aIncluding multiple choices.
bPatients with any line of therapy